We report a case of acute hepatitis B after autologous stem cell transplantation (ASCT) in a patient with lowgrade non-Hodgkin's lymphoma. At diagnosis of the hematological disease, the patient had the characteristic serology of a previous hepatitis B infection, being Ag HBs negative, hepatitis B virus core antibody positive (anti-HBC) and hepatitis B virus surface antibody weakly positive. He developed fatal hepatitis B after autologous stem cell transplantation, suggesting reactivation consequent to immunosuppression.
Intensive therapy in autologous and allogeneic hematological transplantation results in severe impairment of the immune system.
We report a patient with acute viral hepatitis B, which appeared to be a viral reactivation after autologous stem cell transplantation.
In January 1996, a 48-year-old man was admitted to the Hematological Department, with an inguinal mass. He had no previous medical or surgical history. Surgical biopsy supported the diagnosis of follicular small and large cell lymphoma. He had no B symptoms. There was no hepatosplenomegaly or lymphadenopathy on physical examination. A complete evaluation including chest X-ray, thoraco-abdominal CT scan, bone marrow biopsy, and lymphangiography confirmed stage I lymphoma.
Hemoglobin was 13.6 g/dl , WBC 5.5 ϫ 10 9 /l (4.3 polymorphonuclear leukocytes, 0.78 lymphocytes) and platelets 2.1 ϫ 10 9 /l. The serum alanine transaminase level was 14 IU/l ; alkaline phosphatase level was 55 IU/l and LDH level was 170 IU/ml.
He was initially treated with six cycles of chemotherapy, repeated every 3 weeks, including cyclophosphamide, vindesine and prednisone. Complete remission was achieved after chemotherapy. The treatment was completed with infradiaphragmatic radiation therapy (40 Gy).
In October 1996, the disease recurred in the supradiaphragmatic and infradiaphragmatic lymph nodes. No hepatomegaly or splenomegaly was noted on CT scan. Bone marrow biopsy was uninvolved. The serum alanine transaminase level was 37 IU/l and the alkaline phosphatase was 75 IU/l. Serum samples were examined for CMV, HTLV1, HBV, HCV, HIV and were positive only for hepatitis B, virus core antibody (anti-HBC), weakly positive for the hepatitis B virus surface Ag (HBsAg at 3 mIU/ml) and negative for the hepatitis B virus surface antibody (antiHBs).
He received combined chemotherapy with three cycles of chemotherapy (VCAP): 3 mg/m 2 vindesine i.v on day 1, 1.5 g/m 2 cyclophosphamide i.v. on day 2, 80 mg/m 2 adriamycin i.v. on day 2, 80 mg/m 2 /day prednisone orally for 5 days (total dose 400 mg/m 2 ), and achieved a second complete remission. Throughout the chemotherapy cycles liver functions tests were within normal limits. Before peripheral stem cell transplantation, the serum alanine transaminase level was 18 IU/l and alkaline phosphatase level 71 IU/l. At this time, his serologic tests were unchanged.
Between January 1996 and February 1997, he did not need any blood support. In March 1997, intensive consolidation therapy was administered with BEAM (300 mg/m 2 BCNU day 1, 400 mg/m 2 etoposide days 1-4, 140 mg/m 2 melphalan day 5, 400 mg/m 2 aracytine days 1-4), followed by peripheral blood stem cell transplantation, with no major complications. During aplasia, he received six matched red blood cell units. Blood components were obtained from HBsAg-negative volunteer donors.
In May 1997 he developed progressive malaise, anorexia and jaundice, with no clinical encephalopathy. He had no clinical hepatomegaly but did have ascites. The serum aspartate transaminase level was 380 IU/l, serum alanine transaminase 380 IU/ml, bilirubin 469 M/l and phosphatase alkaline 47 IU/l. The prothrombin time (PT) was 30 s. He was serologically tested for HBsAg, anti-HBs, anti-HBc and anti-HCV antibodies, using commercial radioimmunoassays. Virological markers now indicated active HBV infection with HBsAg and anti-HBc IgM. HBV-DNA was negative in serum ( Figure 1 ). Severe acute hepatitis was diagnosed on clinical and biological criteria.
The patient was admitted to the hepatological intensive care unit in Beaujon Hospital. Liver biopsy revealed significant centrolobular necrosis and the presence of HBsAg in hepatocytes. He died of severe sepsis resulting from infected ascites 6 days after admission.
Discussion
We report a fatal case of HBV infection following autologous stem cell transplantation in a patient previously infected with the hepatitis B virus. Hepatic complications occur after ASCT mainly because of aplasia, drug toxicity, venoocclusive disease of the liver, and infections. 1, 2 No hepatic complications were observed in the patient before and during the 2 months following ASCT. Seventy days after ASCT, rapid hepatic failure occurred. HBsAg became positive, associated with anti-HBc IgM.
Two etiological hypotheses can be considered: first, reinfection with hepatitis B virus by nosocomial, sexual or other transmission, secondly, reactivation of the hepatitis virus. Reinfection with a second virus is unlikely because all blood products were screened and were negative for HBV markers, and sexual transmission was unproven. Furthermore, reinfection with a second virus has never been described in the literature, and reactivation of hepatitis B has been observed in patients with AIDS. 3 The second hypothesis, and the most probable, is reactivation of the hepatitis virus as a consequence of immunosuppression. Reactivation of hepatitis B has been described in patients after allogeneic bone marrow transplantation, but has always occurred in patients who had markers of chronic hepatitis B, and were HBsAg positive. [4] [5] [6] Only one case of fatal hepatitis reactivation in a patient who had successfully recovered from a previous HBV infection has been described in 1989 after autologous bone marrow transplantation (ABMT) in a patient with acute lymphoblastic leukemia. 7 It is interesting to note that the liver damage appeared in the same interval as in our patient, about 2 months after ABMT. This supports the theory of Van Dam et al 8 that immune suppression might allow virus replication and infection of hepatocytes. Immune reconstitution after transplantation might have facilitated progressive destruction of virus-infected hepatocytes, resulting in fulminant hepatitis. In conclusion, we suggest that patients with a previous history of hepatitis B (even if HBsAgnegative) who receive immunosuppressive therapy should be carefully monitored.
